NCT00239759

Brief Summary

The goal of MIRAGE is to evaluate the association of genetic and non-genetic risk factors for Alzheimer's Disease.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2002

Longer than P75 for all trials

Geographic Reach
4 countries

15 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2002

Completed
3.1 years until next milestone

First Submitted

Initial submission to the registry

October 13, 2005

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 17, 2005

Completed
2.6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2008

Completed
Last Updated

February 25, 2009

Status Verified

February 1, 2009

First QC Date

October 13, 2005

Last Update Submit

February 24, 2009

Conditions

Alzheimer's Disease

Keywords

Epidemiological study

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • NOTE: This trial accepts patients with Probable AD, and their cognitively normal brothers or sisters
  • Probable or definite AD by NINCDS-ADRDA criteria
  • Living siblings who are cognitively normal as measured by a brief standardized cognitive assessment
  • Ages 60 and over for Alzheimer's disease patients
  • Ages 50 and over for cognitively normal siblings

You may not qualify if:

  • Early onset Alzheimer's disease attributed to APP, PS1 or PS2 gene mutations
  • History of clinical stroke
  • Siblings whose cognitive assessment does not meet study criteria
  • Pacemaker or other contraindication to MRI

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (15)

University of Alabama

Birmingham, Alabama, 35233, United States

Location

Sun Health Research Institute

Sun City, Arizona, 85351, United States

Location

Rancho Los Amigos National Rehabilitation Center/University of Southern California

Downey, California, 90242, United States

Location

University of California, Davis

Sacramento, California, 95817, United States

Location

Howard University

Washington D.C., District of Columbia, 20060, United States

Location

University of Miami School of Medicine

Miami Beach, Florida, 33140, United States

Location

Morehouse School of Medicine

Atlanta, Georgia, 30310, United States

Location

Pacific Health Research Institute

Honolulu, Hawaii, 96817, United States

Location

Indiana University School of Medicine

Indianapolis, Indiana, 46202, United States

Location

Boston University School of Medicine

Boston, Massachusetts, 02118, United States

Location

Cornell Medical University

New York, New York, 10021, United States

Location

Case Western Reserve University

Cleveland, Ohio, 44106, United States

Location

University of British Columbia

Vancouver, British Columbia, V6T 2B5, Canada

Location

Technical University of Munich

Munich, P-81675, Germany

Location

G. Papanicolaou Hospital

Exholi Thessaloniki, S7010, Greece

Location

Related Publications (5)

  • Bachman DL, Green RC, Benke KS, Cupples LA, Farrer LA; MIRAGE Study Group. Comparison of Alzheimer's disease risk factors in white and African American families. Neurology. 2003 Apr 22;60(8):1372-4. doi: 10.1212/01.wnl.0000058751.43033.4d.

    PMID: 12707449BACKGROUND

  • Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, Kukull WA, Chui H, Edeki T, Griffith PA, Friedland RP, Bachman D, Farrer L. Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol. 2003 May;60(5):753-9. doi: 10.1001/archneur.60.5.753.

    PMID: 12756140BACKGROUND

  • Henderson VW, Benke KS, Green RC, Cupples LA, Farrer LA; MIRAGE Study Group. Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J Neurol Neurosurg Psychiatry. 2005 Jan;76(1):103-5. doi: 10.1136/jnnp.2003.024927.

    PMID: 15608005BACKGROUND

  • Yip AG, Green RC, Huyck M, Cupples LA, Farrer LA; MIRAGE Study Group. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study. BMC Geriatr. 2005 Jan 12;5:2. doi: 10.1186/1471-2318-5-2.

    PMID: 15647106BACKGROUND

  • Yip AG, McKee AC, Green RC, Wells J, Young H, Cupples LA, Farrer LA. APOE, vascular pathology, and the AD brain. Neurology. 2005 Jul 26;65(2):259-65. doi: 10.1212/01.wnl.0000168863.49053.4d.

    PMID: 16043796BACKGROUND

Related Links

MeSH Terms

Conditions

Alzheimer Disease

Condition Hierarchy (Ancestors)

DementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental Disorders

Study Officials

  • Lindsay Farrer, PhD

    Chief, Genetics Program, Boston University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Sponsor Type
NIH

Study Record Dates

First Submitted

October 13, 2005

First Posted

October 17, 2005

Study Start

September 1, 2002

Study Completion

June 1, 2008

Last Updated

February 25, 2009

Record last verified: 2009-02

Locations

GR(1)CA(1)DE(1)US(12)